Literature DB >> 22764174

Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.

Yanqing Sun1, Mei Li, Peter B Gilbert.   

Abstract

For time-to-event data with finitely many competing risks, the proportional hazards model has been a popular tool for relating the cause-specific outcomes to covariates (Prentice and others, 1978. The analysis of failure time in the presence of competing risks. Biometrics 34, 541-554). Inspired by previous research in HIV vaccine efficacy trials, the cause of failure is replaced by a continuous mark observed only in subjects who fail. This article studies an extension of this approach to allow a multivariate continuum of competing risks, to better account for the fact that the candidate HIV vaccines tested in efficacy trials have contained multiple HIV sequences, with a purpose to elicit multiple types of immune response that recognize and block different types of HIV viruses. We develop inference for the proportional hazards model in which the regression parameters depend parametrically on the marks, to avoid the curse of dimensionality, and the baseline hazard depends nonparametrically on both time and marks. Goodness-of-fit tests are constructed based on generalized weighted martingale residuals. The finite-sample performance of the proposed methods is examined through extensive simulations. The methods are applied to a vaccine efficacy trial to examine whether and how certain antigens represented inside the vaccine are relevant for protection or anti-protection against the exposing HIVs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22764174      PMCID: PMC3520499          DOI: 10.1093/biostatistics/kxs022

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  13 in total

1.  Multiple imputation methods for estimating regression coefficients in the competing risks model with missing cause of failure.

Authors:  K Lu; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Tests for comparing mark-specific hazards and cumulative incidence functions.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Lifetime Data Anal       Date:  2004-03       Impact factor: 1.588

3.  Leveraging information across HLA alleles/supertypes improves epitope prediction.

Authors:  David Heckerman; Carl Kadie; Jennifer Listgarten
Journal:  J Comput Biol       Date:  2007 Jul-Aug       Impact factor: 1.479

4.  The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Biostatistics       Date:  2007-08-17       Impact factor: 5.899

5.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

6.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

7.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

8.  PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.

Authors:  Yanqing Sun; Peter B Gilbert; Ian W McKeague
Journal:  Ann Stat       Date:  2009-02-01       Impact factor: 4.028

9.  Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks.

Authors:  Yanqing Sun; Peter B Gilbert
Journal:  Scand Stat Theory Appl       Date:  2012-03       Impact factor: 1.396

10.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Authors:  Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins
Journal:  Nat Med       Date:  2011-02-27       Impact factor: 53.440

View more
  6 in total

1.  Mark-specific hazard ratio model with missing multivariate marks.

Authors:  Michal Juraska; Peter B Gilbert
Journal:  Lifetime Data Anal       Date:  2015-10-28       Impact factor: 1.588

2.  Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.

Authors:  Yanqing Sun; Mei Li; Peter B Gilbert
Journal:  Comput Stat Data Anal       Date:  2014-12-03       Impact factor: 1.681

3.  Sieve analysis using the number of infecting pathogens.

Authors:  Dean Follmann; Chiung-Yu Huang
Journal:  Biometrics       Date:  2017-12-14       Impact factor: 2.571

4.  Mark-specific additive hazards regression with continuous marks.

Authors:  Dongxiao Han; Liuquan Sun; Yanqing Sun; Li Qi
Journal:  Lifetime Data Anal       Date:  2016-05-11       Impact factor: 1.588

5.  Variable selection for a mark-specific additive hazards model using the adaptive LASSO.

Authors:  Dongxiao Han; Lianqiang Qu; Liuquan Sun; Yanqing Sun
Journal:  Stat Methods Med Res       Date:  2021-07-15       Impact factor: 2.494

6.  Assessing trends in vaccine efficacy by pathogen genetic distance.

Authors:  David Benkeser; Michal Juraska; Peter B Gilbert
Journal:  J Soc Fr Statistique (2009)       Date:  2020-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.